Skip to main content
Clinical Trials/NCT03217487
NCT03217487
Unknown
Not Applicable

A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft for the Treatment of Limbal Stem Cell Deficiency

Chunxiao Wang1 site in 1 country20 target enrollmentStarted: July 25, 2017Last updated:

Overview

Phase
Not Applicable
Sponsor
Chunxiao Wang
Enrollment
20
Locations
1
Primary Endpoint
Restoration of corneal surface in the diseased eye

Overview

Brief Summary

The purpose of the study is to explore whether femtosecond laser-assisted corneal epithelial autograft is more effective than limbal conjunctival autograft for ocular surface reconstruction in patients with limbal stem cell deficiency (LSCD).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
14 Years to 80 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Unilateral LSCD secondary to ocular burns, with the duration of disease of at least 24 months at the time of screening visit;
  • Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea;
  • Informed consent signed by patient or legal guardian. Having the ability to comply with study assessments for the full duration of the study.

Exclusion Criteria

  • LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement;
  • LSCD by ocular surface disorders other than pterygium;
  • Eyelids malposition;
  • The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm;
  • High myopia with a spherical equivalent of -15.0 D or less;
  • Corneal or ocular surface infection within 30 days prior to study entry;
  • Ocular surface malignancy;
  • Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
  • Renal failure with creatinine clearance\< 25ml/min;
  • Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L;

Outcomes

Primary Outcomes

Restoration of corneal surface in the diseased eye

Time Frame: 1 year

Restoration of a completely epithelized, stable, and avascular corneal surface in the diseased eye.

Restoration of corneal surface in the fellow eye

Time Frame: 1 year

Restoration of a completely epithelized, stable, and avascular corneal surface in the fellow eye.

Secondary Outcomes

  • Uncorrected and best-corrected visual acuity in both eyes(1 year)
  • Corneal power, astigmatism and aberration in both eyes(1 year)
  • Corneal sensation in both eyes(1 year)
  • Corneal thickness in both eyes(1 year)
  • Density of stromal nerve and stromal keratocytes in both eyes(1 year)
  • Reconstruction of limbal palisades of Vogt in the diseased eye(1 year)
  • Corneal haze in both eyes(1 year)

Investigators

Sponsor
Chunxiao Wang
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Chunxiao Wang

Clinical investigator

Sun Yat-sen University

Study Sites (1)

Loading locations...

Similar Trials